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Abstract
AMP-activated protein kinase (AMPK) is a regulatory
kinase coupling cellular metabolism with ion transport.
Madin-Darby Canine Kidney-Clone 7 (MDCK-C7) cells
possess characteristics of the renal principal cell type,
express the cystic fibrosis transmembrane regulator
and the epithelial Na+ channel, and display NPPB and
amiloride-sensitive transepithelial transport when
stimulated with [Arg8]-vasopressin. [Arg8]-vasopressin
binding to its receptor on the basolateral membrane
of MDCK-C7 results in cAMP production, activation
of cAMP-dependent protein kinase A (PKA), and
increases in Cl- and Na+ transport. Ussing-style
electrophysiology showed that the PKA inhibitor, H89,
blocked Cl- and Na+ transport. Unexpectedly, [Arg8]-
vasopressin stimulation resulted in the
dephosphorylation of pAMPKthr172. H89 did not prevent
this, suggesting that the dephosphorylation is
independent of PKA. 24 hour, but not 15 minute,
incubation with the AMPK activator, AICAR, also
blocked [Arg8]-vasopressin-stimulated currents.
Contrary to previous studies, immunoblotting revealed
that AICAR did not increase abundance of the active,
phosphorylated form of AMPK (pAMPKthr172); although,
AICAR treatment significantly blocked [Arg8]-
vasopressin -stimulated cAMP production. [Arg8]-
vasopressin still caused pAMPKthr172 dephosphory-
lation in the presence of AICAR, suggesting that this
effect is also independent of cAMP. In summary, these
data suggest [Arg8]-vasopressin regulates AMPK
phosphorylation and that AICAR inhibits ion transport
independently of AMPK in MDCK-C7 cells.
Introduction
[Arg8]-vasopressin binding to the V2 receptor on
the basolateral membrane of principal cells results in
production of cAMP and concomitant activation of cAMP-
dependent protein kinase A (PKA). This enzyme plays
multiple roles in the cell, one of which is the regulation of
ion transport processes, including Cl- and Na+ transport
via the cystic fibrosis transmembrane conductance
regulator (CFTR) and epithelial Na+ channel (ENaC),
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respectively [1, 2]. The activities of the aforementioned
ion channels in various epithelial cell models (human
colonic adenocarcinoma T84 cells, mouse principal kidney
cortical collecting duct clone 4 cells, and human lung
adenocarcinoma H441 cells) have also been shown to be
negatively regulated by AMP-activated protein kinase
(AMPK) [3-8]. Moreover, AMPK has been reported to
regulate transporters other than CFTR and ENaC,
including the Na+/K+/2Cl- co-transporter (NKCC) and the
Na+/K+ ATPase [8, 9]. AMPK has therefore been
described as a cellular energy-ion transport coupling kinase
[10].
AMPK is a serine/threonine (ser/thr) protein kinase
composed of a catalytic (α) and regulatory subunits (β
& γ), each of which are expressed as multiple isoforms
[11]. The activity of this enzyme can be regulated by
changes in cellular adenosine monophosphate/adenosine
triphosphate (AMP/ATP) ratios during periods of cellular
stress. The binding of AMP to the catalytic subunit of
AMPK causes an allosteric change allowing the enzyme
to be more easily phosphorylated and activated by
upstream AMPK kinases (AMPKKs). Known AMPKKs
include LKB1, the calcium/calmodulin-dependent protein
kinase kinases α and β (CaMMKα & CaMMKβ) and
transforming growth factor-β-activated kinase (TAK1)
[11]. Each AMPKK can phosphorylate the thr172 position
of the AMPKα subunit. Thr172 has been the most
intensively studied phosphorylation site on AMPK and is
considered to be important in determining the degree of
enzyme activation.
The Madin-Darby Canine Kidney-Clone 7 (MDCK-
C7) cell line is a continuous cell line derived from dog
principal cells. These epithelial cells, in contrast to MDCK-
C11 cells, have retained multiple characteristics of the
renal principal cell type, including high transepithelial
resistances (≥ 1000 Ω•cm2) and Na+-retaining responses
to aldosterone, insulin-like growth factor-1, and [Arg8]-
vasopressin [12-14]. Moreover, MDCK-C7 cells express
CFTR, as do in vivo kidney cells [15-19]. For these
reasons, this principal cell model was chosen to test the
hypothesis that AMPK regulates CFTR and ENaC-
mediated ion transport stimulated by [Arg8]-vasopressin.
We report for the first time, that [Arg8]-vasopressin inhibits
AMPK activity. In addition, the AMPK activator, 5-
Aminoimidazole-4-carboxyamide ribonucleoside
(AICAR) inhibits [Arg8]-vasopressin stimulated Cl- and
Na+ flux. However, this effect of AICAR  is independent
of AMPK activation and is, at least in part, the result of
an inhibition of cAMP production in response to [Arg8]-
vasopressin. These data highlight the complex interaction
between cAMP and AMPK signaling pathways and show
that AICAR can elicit AMPK-independent effects on ion
transport processes in MDCK-C7 cells.
Materials and Methods
Materials
Madine Darby Canine Kidney, clone-7 (MDCK-C7) cells
were a kind gift from Prof. Hans Oberliethner (Meunster,
Germany). H89 and AICAR were purchased from Biomol
(Plymouth Meeting, PA) and prepared in DMSO. [Arg8]-
vasopressin was purchased as a solution and okadaic acid
(OA) was prepared in DMSO. Both were from Sigma Aldrich
(St. Louis, MO). Amiloride, also from Sigma Aldrich, was
prepared in double-distilled water. Nystatin was prepared in
DMSO and was from Sigma Aldrich. Primary antibodies (raised
in rabbit) directed against αAMPK, phospho-αAMPKthr172,
ACC, and phospho-ACCser79 were from Cell Signaling (Danvers,
MA). The antibodies used for αAMPK and phospho-
αAMPKthr172 detection recognize both α1 and α2 isoforms of
AMPK. The antibodies used for ACC and phospho-ACCser79
detection recognize both αACC and βACC. The anti-LKB1
antibody was from Abcam (Cambridge, MA). Mouse anti-β-
actin antibody was purchased from Novus Biologicals
(Littleton, CO). Goat-anti rabbit-HRP and goat anti-mouse-HRP
secondary antibodies were purchased from Upstate (Lake
Placid, NY). The Direct Cyclic AMP Enzyme Immunoassay Kit
was from Assay Designs, Inc. (Ann Arbor, MI).
Cell culture
MDCK-C7 cells were cultured at 37°C in a humified
incubator gassed with 5% CO2. Culture media consisted of
DMEM/F12 base media (Invitrogen, Carlsbad, CA)
supplemented with 5% fetal bovine serum (ICN Biochemicals
Inc., Irvine, CA), 1 mM glutamax®, 25 U/mL penicillin, 25 mg/mL
streptomycin (Invitrogen), and 12 mg/L ciprofloxacin
(Mediatech Inc., Herndon, VA). Cells were maintained in plastic
culture flasks. For electrophysiological and biochemical
analyses, the cells were subcultured onto permeable supports
(Costar® Transwells, Corning, Acton, MA) for at least 14 days.
Fresh media was supplied to all cell cultures three times per
week.
Electrophysiology
Ussing-style electrophysiology was used to investigate
net transepithelial ion flux in the form of short-circuit current
(SCC). Cells grown on 0.4 μM Costar® Transwell filters were
assembled into Ussing chambers; the potential difference was
clamped to zero and the resulting SCC measured. Transepithelial
resistance was monitored throughout the entire duration of
each electrophysiological experiment by applying a 2mV pulse
every 200 seconds. Only cells that maintained a resistance
≥ 1000 Ω•cm2 were included in statistical analyses. For
electrophysiological experiments, [Arg8]-vasopressin (100mU/
mL) was added to the serosal bathing media; H89 (20μM) or
vehicle (DMSO) was added bilaterally; amiloride (10μM) was
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added to the apical bathing media.
For experiments involving nystatin, physiological Cl-
Ringers solution (in mM; 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44
KH2PO4, 1.3 CaCl2, 0.5 MgCl2, 4.2 NaHCO3, 10 HEPES, 5 D-
glucose, pH 7.2 with Tris-base) or low Cl- Ringers solution (in
mM; 2.5 NaCl, 133.3 sodium gluconate, 5 potassium gluconate,
0.36 K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2 NaHCO3,
10 HEPES, 5 D-glucose, pH 7.2 with Tris-base) were used to
bath cultures during SCC experiments. The final Cl-
concentrations were 149mM and 14.9mM, respectively.
Immunoblotting
MDCK-C7 cells grown on permeable supports were
washed twice with cold Hank’s Balanced Salt Solution
(Mediatech Inc., Herndon, VA). Cell lysis buffer (4% SDS, 10%
glycerol in 0.5 M Tris, pH 6.8) was added directly to epithelial
cultures and cells were scraped with a rubber policeman. 9 μL
protease inhibitor cocktail (Sigma) per mL cell lysis buffer was
added to prevent protein degradation. Protein concentrations
in samples were determined with the DC protein assay (Biorad,
Hercules, CA). 20 μg of protein were separated by SDS-PAGE
on 7.5% acrylamide gels and transferred onto PVDF blotting
membrane. Membranes were blocked for 1 hr at room
temperature in 5% BSA diluted in wash buffer (0.01% Tween-
20 in TBS, pH 7.6). All primary antibodies were diluted in 5%
BSA diluted in wash buffer. Membranes were incubated with
primary antibody overnight at 4°C, and then incubated in 3
changes of wash buffer for 5 min. each. This was followed by 1
hr incubation in secondary antibody, diluted with 5% milk in
wash buffer, at room temperature. Three, 5 min. incubations in
wash buffer followed. Protein bands were visualized with West
Dura Enhanced Chemiluminescent Reagent and developed
either on ClearBlue film (Pierce, Rockford, IL) or with a Molecular
Imager ChemiDoc XRS System (Biorad). In order to compare
relative amounts of pACCser79 and pAMPKthr172, as well as ACC
and AMPK, PVDF blotting membranes were cut lengthwise
after transfer at ~ 75 kDa and 50 kDa. This yielded three pieces
of membrane for immunoblotting - one for pACCser79 or ACC,
one for pAMPKthr172 or AMPK, and one for β-actin (loading
control).
Nucleotide Extraction and High Performance Liquid
Chromatography
Polarized MDCK-C7 cells were washed twice with ice-
cold HBSS on ice. Cells were scraped in 500 μL 0.4 M cold
perchloric acid on ice and spun for 3 min. at 9825 x g. A fixed
volume of supernatant was removed and neutralized with 3 M
K3PO4 and extracts were analyzed with high performance liquid
chromatography (HPLC) according to the reverse-phase
procedures described previously [20, 21]. The equipment used
was the Hewlett-Packard 1100 series linked to a diode array
detector. The perchlorate precipitate was re-suspended in 500
μL 0.5 M NaOH and the protein content was determined using
a Bradford assay.
Fig. 1. PKA is required for [Arg8]-
vasopressin -stimulated increases
in SCC. Panel A: Polarized MDCK-
C7 cells were assembled into
Ussing chambers and allowed to
stabilize. 10 min prior to stimulation
with [Arg8]-vasopressin (100mU/
mL), vehicle (DMSO) or H89 (20
µM) was added to the apical and
serosal bathing compartments.
Panel B: While in culture, polarized
MDCK-C7 cells were treated as
those in Panel A, except for 24 hrs.
After assembly into Ussing
chambers, vehicle or H89 was re-
added to the apical and serosal
bathing compartments. All cells
were stimulated with [Arg8]-
vasopressin (100 mU/mL) at t = 0
min on the time scale. Amiloride (10
μM) was added 30 min. later. The
entire duration of the electro-
physiology experiments are depicted in the left panels, in which three separate increases in SCC are evident. The middle panels
show an expanded timescale emphasizing the effect of H89 on the first increase (Cl- secretion) in SCC elicited by the addition of
[Arg8]-vasopressin. In the right panels, the magnitude of Cl- secretion and Na+ reabsorption (SCCamil) was calculated as SCCt=0.4min
- SCCt=0min and SCCt=35min - SCCt=30min, respectively. The magnitudes in H89-treated cells were normalized to those in matched
vehicle-treated cells. H89 did not cause any significant changes in transepithelial resistance. Symbols and bars represent the
mean ± SEM for 7 individual experiments where *p ≤ 0.001 by a one-way ANOVA followed by Tukey’s post-hoc test. Vaso, [Arg8]-
vasopressin; amil, amiloride.
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cAMP Assay
Polarized MDCK-C7 cells were treated serosally and
apically with DMSO or AICAR (1mM) for 24 hrs followed by
stimulation with or without [Arg8]-vasopressin (100mU/mL) for
10 seconds. Each culture was washed twice with 37°C Hank’s
Balanced Salt Solution and incubated for 10 min. with 1% Triton
X-100 in 0.1M HCl at 37°C. Lysates were centrifuged for 1 min.
at 14,243 x g to remove cellular debris. Protein concentrations
and cAMP concentrations per sample were determined with
the RC/DC Protein Assay and the Direct Cyclic AMP Enzyme
Immunoassay Kit, respectively. Final cAMP concentrations
were calculated as pmol cAMP/mg protein.
Statistics
Differences between two or more groups in a given
experiment were analyzed by a one-way ANOVA followed by a
Tukey’s post-hoc test using SPSS 14.0 statistical software.
Student’s t-test was used to analyze experiments containing
only two groups. Differences were considered significant where
p ≤ 0.05. Symbols in line and bar graphs represent means ±
SEM. Line and bar graphs were generated using Sigma Plot
2000 graphing software.
Results
Effect of [Arg8]-vasopressin on ion transport
Stimulation with [Arg8]-vasopressin induces a
triphasic increase in transepithelial ion transport, measured
as SCC, in MDCK-C7 principal cells. This
electrophysiological response has been previously
characterized by ourselves as transient Cl- secretion via
CFTR, followed by a putative calcium-activated K+ flux,
and finally reabsorptive Na+ movement via ENaC [13]
(Fig. 1A and B). The increase in Cl- secretion and Na+
reabsorption elicited by [Arg8]-vasopressin stimulation
were significantly blocked by short-term (10 min) and
long-term (24 hr) treatment with H89, a PKA inhibitor
(Fig. 1A and B respectively), supporting a role for the
PKA signaling pathway in mediating these ion transport
events.
Effect of [Arg8]-vasopressin on AMPK activity
Activation of AMPK has been shown to negatively
regulate CFTR and ENaC in multiple epithelial cell models
[3-8]. Therefore, we postulated that changes in [Arg8]-
vasopressin -stimulated SCC may involve AMPK as well
as PKA. To verify the contribution of each kinase, control
cells and those treated with H89 were analyzed for
changes in the active, phosphorylated form of AMPK
(pAMPKthr172). Acetyl co-A carboxylase (ACC) is a
downstream target of AMPK. Accordingly, we used the
phosphorylation of ACC at ser79 to confirm activation of
Fig. 2. [Arg8]-vasopressin dephosphorylates AMPK
independently of PKA. Polarized MDCK-C7 cells were treated
with either vehicle (DMSO) or H89 (20 μM) bilaterally for 10
min or 24 hrs and stimulated with [Arg8]-vasopressin (100 mU/
mL) for ~20 seconds prior to lysis. Cells were solubilized and
proteins were separated by SDS-PAGE and transferred to PVDF
in preparation for immunoblotting. PVDFs were cut into thirds
and probed for pACCser79 and pAMPKthr172 (upper panels) or
ACC and AMPK (lower panels). β-actin served as a loading
control. Bands corresponding to the predicted molecular
weights of ACC & pACCser79 (180 kDa), AMPK & pAMPKthr172
(62 kDa) and actin (42 kDa) were detected. This is a
representative immunoblot of three individual experiments. The
numbers 1-6 refer to the lane number.
AMPK. Fig. 2 shows that no changes in pAMPKthr172 or
pACCser79 were detected in the presence of short-term
(10min) or long-term (24hrs) H89 (compare lanes 1, 3, &
5 or 2, 4, & 6). Unexpectedly, stimulation with [Arg8]-
vasopressin resulted in a dramatic reduction of
pAMPKthr172, which was translated to pACCser79. These
changes were independent of any changes in the total
protein pools of AMPK and ACC (compare lanes 1 &
2). In addition, the dephosphorylation of AMPK and ACC
by [Arg8]-vasopressin was not affected by H89 (compare
lanes 3 & 5 or 4 & 6). Taken together these data indicate
that [Arg8]-vasopressin reduces AMPK activity but this
effect is not mediated via PKA or cAMP.
Effect of AICAR on [Arg8]-vasopressin -stimulated
ion transport
To further investigate the role of AMPK on [Arg8]-
vasopressin stimulated ion transport we used AICAR, an
AMP analogue known to result in the activation of AMPK.
Fig. 3A shows that short-term (15 min) incubation with
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Fig. 3. AICAR inhibits [Arg8]-vasopressin -stimulated ion transport. Panel A: Polarized MDCK-C7 cells were
assembled into Ussing chambers and allowed to stabilize. 15 min prior to stimulation with [Arg8]-vasopressin
(100mU/mL), vehicle (DMSO) or AICAR (1 mM) was added to the apical and serosal bathing compartments.
Panel B: While in culture, polarized MDCK-C7 cells were treated as those in Panel A, except for 24 hrs. After
assembly into Ussing chambers, vehicle or AICAR was re-added to the apical and serosal bathing compartments.
All cells were stimulated with [Arg8]-vasopressin (100 mU/mL) at t = 0 min on the time scale. Amiloride (10 μM)
was added 30 min. later. The entire duration of the electrophysiology experiments are depicted in the left
panels. The right panels show an expanded timescale emphasizing the effect of AICAR on Cl- secretion elicited
by the addition of [Arg8]-vasopressin. In the right panels, the magnitude of Cl- secretion and amount of SCCamil
was calculated as SCCt=0.4min - SCCt=0min and SCCt=35min - SCCt=30min, respectively. The magnitudes in AICAR-
treated cells were normalized to that in matched vehicle-treated cells.  AICAR did not cause any significant
changes in transepithelial resistances. Symbols and bars represent the mean ± SEM for 14 individual experiments
where *p ≤ 0.02  by a one-way ANOVA followed by Tukey’s post-hoc test. Vaso, [Arg8]-vasopressin; amil,
amiloride.
AICAR was without effect on ion transport induced by
[Arg8]-vasopressin. Conversely, long-term (24 hrs)
challenge with AICAR significantly blocked [Arg8]-
vasopressin induced Cl- secretion (by ~47.1 ± 9.0%) and
Na+ reabsorption (by ~54.3 ± 12.2%) (Fig. 3B). We also
permeabilized the basolateral membrane with nystatin,
thereby eliminating any ion conductances that alter Cl-
secretion, and imposed a Cl- gradient across the
epithelium. AICAR (24 hrs) significantly inhibited apical
Cl- secretion under permeabilized conditions, suggesting
that the compound is affecting the activity of Cl- channels
located in the apical membrane (Fig. 4).
Effect of AICAR on AMPK activity
To verify the involvement of AMPK in the observations
described in the previous section, cells treated both short-
and long-term with AICAR were analyzed for
pAMPKthr172 and pACCser79 abundances. It is shown in
Fig. 5 that AICAR did not result in any substantial changes
in the abundance of pAMPKthr172 at either incubation
period (compare lanes 1 & 3, 2 & 4, 5 & 7, or 6 & 8).
Moreover, [Arg8]-vasopressin caused a similar decrease
in pAMPKthr172 and pACCser79 levels in the presence of
AICAR as previously observed in the absence of AICAR
(refer to Fig. 2). These data indicate that AICAR
decreases Cl- secretion and Na+ reabsorption inde-
pendently of AMPK activation.
Effect of AICAR on cAMP
[Arg8]-vasopressin elevates cAMP and activates
PKA to increase CFTR and ENaC activity. We therefore
investigated the effect of AICAR on total cellular cAMP
 Vasopressin Regulation of AMPK Cell Physiol Biochem 2008;22:487-496
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Fig. 4. Basolateral membrane permeabilization does not rescue AICAR-induced inhibition of Cl- secretion. While in culture,
polarized MDCK-C7 cells were treated serosally with DMSO (vehicle, black circles) or AICAR (1mM, white circles) for 24 hrs.
Cells were subsequently assembled into Ussing chambers. Cultures in panel A were bathed in symmetrical Ringers solution
([Cl-] = 150 mM). Cultures in panel B were bathed in asymmetrical Ringers solution ([Cl-]apical = 15 mM, [Cl
-]serosal = 150 mM) and
treated with nystatin (280 U/mL) 30 min. prior to hormone stimulation. All cultures were treated apically with amiloride 10 min. prior
to stimulation with [Arg8]-vasopressin (at time = 0 min) to block Na+ reabsorption via ENaC. Panel C: The magnitude of [Arg8]-
vasopressin-stimulated Cl- transport in AICAR-treated cultures was normalized to that of the respective (permeabilized or non-
permeabilized) vehicle-treated cultures and expressed as a percent. AICAR did not cause any significant changes in transepithelial
resistance. Bar graphs represent the mean ± SEM of 3 experiments, where *p ≤ 0.05 compared to the vehicle-treated as determined
by a one-way ANOVA followed by Tukey’s post-hoc test. The magnitude of Cl- secretion from non-permeabilized cultures treated
with AICAR was not statistically different from that in permeabilized cultures. Vaso = [Arg8]-vasopressin.
Fig. 5. AICAR does not regulate AMPK phosphorylation in
MDCK-C7 cells. Polarized MDCK-C7 cells were treated either
with vehicle (DMSO) or AICAR (1mM) bilaterally for 15 minutes
or 24 hrs and stimulated with [Arg8]-vasopressin (100mU/mL)
for ~20 seconds prior to lysis. Cells were solubilized and proteins
were separated by SDS-PAGE and transferred to PVDF in
preparation for immunoblotting. PVDFs were cut into thirds
and probed for pACCser79 and pAMPKthr172 (upper panels) or
ACC and AMPK (lower panels). β-actin served as a loading
control. Bands corresponding to the predicted molecular
weights of ACC & pACCser79 (180 kDa), AMPK & pAMPKthr172
(62 kDa) and actin (42 kDa) were detected. This is a
representative immunoblot of three individual experiments. The
numbers 1-8 refer to the lane number.
Fig. 6. AICAR inhibits cAMP production. Polarized MDCK-
C7 cells were treated with vehicle (DMSO) or AICAR (1 mM)
bilaterally for 15 min (hashed bars) or 24 hrs (solid bars),
stimulated with or without [Arg8]-vasopressin (100 mU/mL) for
~20 sec and assayed for cAMP content. Bars represent the
means ± SEM for 6 individual experiments. *p ≤ 0.05 by a one-
way ANOVA followed by Tukey’s post-hoc test.
levels. Surprisingly, both short- and long-term challenge
with AICAR inhibited cAMP production following [Arg8]-
vasopressin stimulation (Fig. 6). These results are only
partially consistent with the ion transport results described
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Fig. 7. Longterm AICAR treatment lowers GDP/GTP but does not affect total adenine nucleotide levels. Polarized MDCK-C7
cells were treated bilaterally for 24 hrs with vehicle (DMSO) or AICAR (1 mM) and stimulated with or without [Arg8]-vasopressin
(100 mU/mL) for ~20 sec. Cells were prepared for nucleotide extraction and HPLC. Nucleotide levels were normalized to the
amount of protein in each sample. Bars represent the means ± SEM for 3 individual experiments containing 3 replicates each.
*p ≤ 0.05 by a one-way ANOVA followed by Tukey’s post-hoc test. ATP, adenosine triphosphate; ADP, adenosine diphosphate;
AMP, adenosine monophosphate; NAD, nicotinamide dinucleotide; GTP, guanosine triphosphate; GDP, guanosine diphosphate;
TAN, total adenine nucleotide.
Fig. 8. LKB1 is not expressed in three separate principal cell
lines. Polarized H441 (lane 1), A6 (lane 2), mpkCCDcl4 (lane 3),
and MDCK-C7 (lane 4) cells were solubilized. Equal amounts
of protein were separated by SDS-PAGE and transferred to
PVDF in preparation for immunoblotting. The predicted
molecular weight of LKB1 is 48 kDa, however, the antibody
used to identify the protein is advertised to detect a 55 kDa
band. A prominent band of ~56 kDa was detected in H441 cells.
A faint band was detected in A6 cells, and no band was detected
in either the mpkCCDcl4 or MDCK-C7 cells. This image is
representative of one experiment.
Fig. 9. Okadaic acid prevents AMPK and ACC dephospho-
rylation. Polarized MDCK-C7 cells were treated with vehicle
(DMSO) or okadaic acid (1 μM) bilaterally for 30 minutes
and stimulated with or without [Arg8]-vasopressin (100 mU/
mL) for ~20 seconds prior to lysis. Cells were solubilized and
proteins were separated by SDS-PAGE and transferred to PVDF
in preparation for immunoblotting. PVDFs were cut into thirds
and probed for pACCser79 and pAMPKthr172 (upper panels)
or ACC and AMPK (lower panels). β-actin served as a loading
control. Bands corresponding to the predicted molecular
weights of ACC & pACCser79 (180 kDa), AMPK & pAMPKthr172
(62 kDa) and actin (42 kDa) were detected. This is a
representative immunoblot of three individual experiments.
The numbers 1-4 refer to the lane number.
in Fig. 3, where only long-term AICAR treatment, but
not short-term, significantly blocked ion transport.
Effect of AICAR and [Arg8]-vasopressin on
cellular nucleotides
The cellular nucleotide pool has been demonstrated
to change in cells treated with AICAR. We investigated
whether such changes may underlie the effects elicited
by AICAR. Long-term AICAR treatment caused a
significant increase in total adenine nucleotide
concentrations, which was not altered after [Arg8]-
vasopressin stimulation (Fig. 7). This can be attributed to
an increase in both AMP and ATP; however, no changes
in the AMP/ATP ratio were detected. AICAR signifi-
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cantly decreased GDP concentrations and increased GTP
concentrations, resulting in a reduced GDP/GTP ratio. In
addition, [Arg8]-vasopressin, did not alter any nucleotide
concentrations. Thus, the [Arg8]-vasopressin -induced
dephosphorylation of AMPK was not via a decrease in
the AMP/ATP ratio, which would result in an allosteric
change in AMPK, making this less able to be
phosphorylated by AMPKKs.
MDCK-C7 cells do not express LKB1
It was unexpected that AICAR did not increase
pAMPKthr172 or cellular nucleotide levels. AICAR-
induced activation of AMPK is thought to require the
upstream kinase, LKB1. Therefore, we hypothesized that
this protein may not be expressed in MDCK-C7 cells.
Fig. 8 shows that no LKB1 could be detected in the
MDCK-C7 cells. Moreover, the Xenopus laevis A6 and
mpkCCDcl4 (mouse principal kidney cortical collecting
duct clone 4) cell lines, both of which model the principal
cell type, showed little to no LKB1 expression. The
protein was however, detected in H441 cells, as
previously shown [7].
Effect of okadaic acid on [Arg8]-vasopressin
induced dephosphorylation of AMPK
As [Arg8]-vasopressin had no effect on cellular
nucleotide pools, we turned our attention to the role of
the ser/thr phosphatases in dephosphorylation of AMPK.
There are 2 families-phosphatase 1 (PP1) and
phosphatase 2 (PP2)-the latter being composed of 3 sub-
families, 2A, 2B, and 2C. Okadaic acid (OA) is a well-
known phosphatase inhibitor, and can be used at
concentrations of up to 1 μM to inhibit PP2A
independently from PP1s, PP2B, or PP2C [22]. As
expected, acute (30 min.) incubation with OA resulted in
substantial increases in both pAMPKthr172 and pACCser79
abundances (Fig. 9). This verifies that PP2A mediates,
Fig. 10. Schematic representation of [Arg8]-vasopressin and
AICAR regulation of AMPK, ENaC and CFTR in MDCK-C7
cells. [Arg8]-vasopressin stimulates CFTR and ENaC activity
by increasing the production of cAMP, which in turn activates
PKA. H89 inhibits PKA activity. In the current studies, AICAR
inhibits the production of cAMP. AMPK can be activated by
increases in AMP/ATP, followed by phosphorylation by
AMPKKs. Conversely, AMPK can be de-activated by
dephosphorylation via PP2A. In the current studies, AMPK is
not activated by AICAR. [Arg8]-vasopressin
dephosphorylates AMPK, probably by PP2A activation. It is
still unknown what role AMPK plays in regulation of CFTR
and ENaC activity in MDCK-C7 cells.
at least in part, the dephosphorylation of pAMPKthr172 to
AMPK. Moreover, OA prevented [Arg8]-vasopressin -
induced dephosphorylation of AMPK indicating that
[Arg8]-vasopressin could dephosphorylate AMPK via
activation of PP2A.
Discussion
It is well established that [Arg8]-vasopressin
orchestrates its effects on Cl- and Na+ transport (through
CFTR and ENaC, respectively) via elevation of cAMP
and activation of PKA. H89 blocks PKA activity by
competing with the ATP-binding site of the kinase [23]
and, consistent with previous studies, we showed that
inhibition of PKA activity inhibited [Arg8]-vasopressin-
induced rises in Cl- and Na+ transport in MDCK-C7 cells.
Interestingly, we also found that [Arg8]-vasopressin
caused a dramatic decrease in pAMPKthr179 levels; an
effect that is independent of PKA since the
dephosphorylation was evident in the presence of H89.
Since phosphorylation of AMPK in epithelial cells has
been shown to decrease Na+ and Cl- transport [3-8] these
data would support a coordinated response to [Arg8]-
vasopressin whereby there is downregulation of an
inhibitory pathway (AMPK) together with an upregulation
of a stimulatory pathway (PKA).
The role of AMPK in ion transport regulation was
further studied using AICAR-a pharmacological activator
of AMPK. SCC studies showed that 15 minute treatment
with AICAR did not significantly alter [Arg8]-vasopressin-
stimulated ion transport. While this was unexpected, as
others have shown decreases in Cl- currents within 2 hrs
of AICAR treatment [4], a 24 hr AICAR treatment did
inhibit [Arg8]-vasopressin-stimulated Cl- and Na+ flux.
AICAR uptake into the cell occurs via nucleoside
transporters, and the compound is then phosphorylated
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into ZMP by adenosine kinase [24]. ZMP activates AMPK
independently of changes in the AMP/ATP ratio.
Previously published literature showed that AICAR
inhibits forskolin-stimulated Cl- currents via activation of
AMPK [4, 5]. Unexpectedly, we could not detect
substantial changes in AMPK activation (as defined by
changes in pAMPKthr179) after short- or long-term
AICAR challenge. These data suggest that in MDCK-
C7 cells, AICAR inhibits ion transport via an AMPK-
independent mechanism. While this is the first report of
such a mechanism in epithelial cells, AICAR-mediated,
AMPK-independent apoptosis has been described in
Jurkat cells [25]. Furthermore, the biological effects of
AICAR in Jurkat cells did not rely on the conversion of
the activator into ZMP. In addition, inhibition of adenosine
kinase prevented the activation of AMPK in human
polarized retinal pigment epithelial cells [26]. Therefore,
low adenosine kinase activity in MDCK-C7 cells may
account for AICAR being unable to activate AMPK. We
found that AICAR caused a significant increase in both
ATP and ADP, which is in direct contrast to a recent
study performed in H441 cells where AICAR significantly
decreased ATP and ADP [8]. AICAR can be further
metabolized into ATP, ADP, and AMP in the cell as it is
an intermediate of the de novo purine biosynthetic
pathway [27]. Thus, our data would support AICAR
conversion to ZMP in MDCK-C7 cells. Why then AICAR
does not activate AMPK in MDCK-C7 cells is not known;
however, AICAR activation of AMPK is thought to require
the upstream kinase, LKB1. We could not detect LKB1
in the MDCK-C7 cells nor two other principal cell models,
the A6 and mpkCCDcl4 cell lines. The antibody used
against LKB1 is reported to cross-react with human,
mouse, and rat. Therefore, the antibody may not recognize
dog LKB1. This is, however, unlikely, in that no LKB1
was detected in the mouse mpkCCDcl4 (an alternative
principal cell line) cells. Thus, it is possible that the absence
of LKB1 and/or other upstream kinases prevents AMPK
activation by AICAR in the MDCK-C7 cells.
As [Arg8]-vasopressin elevates cAMP to stimulate
ion transport, we speculated that 24 hr AICAR challenge
may alter cellular cAMP levels. Surprisingly, both short-
and long-term AICAR treatment inhibited cAMP
production after [Arg8]-vasopressin stimulation. There
was a small rise in cAMP in response to [Arg8]-
vasopressin with 15 min AICAR treatment. Even though
the slight increase in cAMP by [Arg8]-vasopressin was
not significantly different from control-treated cells, there
may still have been enough cAMP to activate ion transport.
Walker et al showed that 48 hour treatment with AICAR
lowered forskolin-stimulated Cl- currents in mouse colon
and decreased apical CFTR expression in T-84 cells-
effects that were shown without demonstrating activation
of AMPK [6]. Such an effect of AICAR (to lower apical
CFTR expression) is consistent with the permeabilization
studies described in Fig. 4. Therefore, our observation of
decreased Cl- current with 24 hr AICAR challenge may
be a combined effect of lowered cAMP production and
CFTR expression.
Earlier published reports state that PP2A mediates
the dephosphorylation of AMPK at thr172 [22] and that
PP2A is activated by cAMP-elevating agents [28, 29].
We confirmed that PP2A dephosphorylates AMPK in
MDCK-C7 cells using the phosphatase inhibitor, OA.
Moreover, [Arg8]-vasopressin-induced dephosphorylation
of AMPK is reversed by OA, indicating that this effect is
mediated by PP2A. However, the vasopressin stimulated
dephosphorylation of AMPK is independent of cAMP as
demonstrated by the results in Figure 6 showing
vasopressin-induced dephosphorylation in the presence
of AICAR which inhibits cAMP production. Thus, we
speculate that [Arg8]-vasopressin may activate PP2A by
a mechanism that does not rely on increases in cAMP.
In conclusion, [Arg8]-vasopressin stimulates Cl- and
Na+ transport in MDCK-C7 cells via elevation of cAMP
and activation of PKA, and potentially, as shown here,
by inhibition of AMPK. [Arg8]-vasopressin resulted in a
dramatic down-regluation of pAMPKthr179, potentially via
activation of PP2A. AICAR decreased [Arg8]-
vasopressin induced Cl- and Na+ transport by preventing
the elevation of cAMP without activation of AMPK. A
schematic representation of these observations is shown
in Fig. 10. This is the first description in epithelial cells
that [Arg8]-vasopressin is a potent regulator of AMPK
phosphorylation and that AICAR can modify ion transport
independently of AMPK activation. These data show that
the signaling pathways regulating ion channel function in
epithelial cells are undoubtedly complex and vary
considerably between cell types. More work will be
required to elucidate the interactions between these
pathways. In the interim, in the light of these data, we
suggest that biological effects attributed to AICAR (and
thus AMPK) must be analyzed with caution.
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